ValuEngine upgraded shares of CVS Health (NYSE:CVS) from a sell rating to a hold rating in a report published on Tuesday morning.
A number of other research analysts have also recently issued reports on the stock. Bank of America lifted their price objective on shares of CVS Health from $86.00 to $90.00 and gave the company a buy rating in a report on Monday, September 17th. Royal Bank of Canada lifted their price objective on shares of CVS Health to $101.00 and gave the company an outperform rating in a report on Tuesday, September 18th. Tigress Financial reiterated a buy rating on shares of CVS Health in a report on Friday, October 26th. Citigroup reiterated a buy rating and set a $81.00 price objective on shares of CVS Health in a report on Monday, July 9th. Finally, Leerink Swann set a $80.00 price objective on shares of CVS Health and gave the company an outperform rating in a report on Thursday, August 9th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, ten have given a buy rating and two have given a strong buy rating to the company’s stock. CVS Health presently has a consensus rating of Buy and an average price target of $89.38.
CVS opened at $79.83 on Tuesday. CVS Health has a 1-year low of $60.14 and a 1-year high of $83.88. The company has a quick ratio of 1.87, a current ratio of 2.44 and a debt-to-equity ratio of 1.66. The firm has a market capitalization of $80.25 billion, a price-to-earnings ratio of 13.53, a P/E/G ratio of 1.05 and a beta of 0.98.
The company also recently declared a quarterly dividend, which was paid on Thursday, November 1st. Investors of record on Wednesday, October 24th were issued a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a yield of 2.51%. The ex-dividend date was Tuesday, October 23rd. CVS Health’s dividend payout ratio (DPR) is presently 33.90%.
In related news, EVP Lisa Bisaccia sold 21,534 shares of the business’s stock in a transaction dated Monday, October 1st. The shares were sold at an average price of $80.00, for a total transaction of $1,722,720.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Eva C. Boratto sold 13,311 shares of the business’s stock in a transaction dated Monday, September 17th. The stock was sold at an average price of $77.16, for a total transaction of $1,027,076.76. Following the transaction, the executive vice president now owns 55,162 shares in the company, valued at $4,256,299.92. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 43,409 shares of company stock worth $3,392,097. 0.53% of the stock is owned by corporate insiders.
A number of institutional investors have recently added to or reduced their stakes in the stock. Camarda Financial Advisors LLC bought a new stake in CVS Health in the second quarter worth about $102,000. Kiley Juergens Wealth Management LLC bought a new stake in CVS Health in the second quarter worth about $103,000. Legacy Advisors LLC raised its position in CVS Health by 7,100.0% in the second quarter. Legacy Advisors LLC now owns 1,800 shares of the pharmacy operator’s stock worth $116,000 after acquiring an additional 1,775 shares during the period. Squar Milner Financial Services LLC bought a new stake in CVS Health in the second quarter worth about $122,000. Finally, Canton Hathaway LLC bought a new stake in CVS Health in the third quarter worth about $126,000. Institutional investors and hedge funds own 82.42% of the company’s stock.
CVS Health Company Profile
CVS Health Corporation, together with its subsidiaries, provides integrated pharmacy health care services. It operates through Pharmacy Services and Retail/LTC segments. The Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, Medicare Part D services, mail order, specialty pharmacy and infusion services, retail pharmacy network management services, prescription management systems, clinical services, disease management programs, and medical pharmacy management services.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.